Our venture, Avea, launched a new product called the Stabiliser!

Their team of scientists developed the Stabiliser to help you:
✔️ balance your sugar spikes
✔️ easily maintain a healthy weight
✔️ have more energy and focus - without the post meal sugar crashes!

Handelszeitung published an interesting story about extending the human lifespan mentioning Maximon, Avea Life, Biolytica and our future longevity ventures.

Biolytica’s Co-Founder and CEO, Robert Konrad Maciejewski, and Co-Founder and Chief Program Officer, James Raaff, attended the 9th annual Aging Research and Drug Discovery Meeting at the University of Copenhagen.
 

We are very proud to announce that Dr. Dr. Elisabeth Roider, MD, PhD, MBA joined the Maximon team as a Partner & Chief Scientific and Medical Officer!

Elisabeth is a Harvard and Swiss-trained, internationally renowned physician scientist, working at the University Hospital of Basel and the Harvard Medical School. Her work has resulted in various high-impact publications, patents, and awards. As a Partner & Chief Scientific and Medical Officer at Maximon she is dedicated to bring the field of longevity to the next level.

Read the article about Elisabeth joining the team on Longevity.Technology!

Our Founding Partner, Marc P. Bernegger, participated in a Longevity fireside chat: “How healthy aging and longer lives will be the biggest investment opportunities ahead of us” during the SuperReturn Edge: Healthtech & Biotech online conference, together with Michael Greve, Founder at KIZOO Technology Capital.

Our Founding Partner, Dr. Tobias Reichmuth, gave a keynote speech “Longevity – bigger than Crypto?” at EARD 2022, run by Lifespan.io.

He was joined by Biolytica’s Co-Founder Dr. Robert Konrad Maciejewski and Avea Life’s Co-Founder Sophie Chabloz, who participated in a panel.

The exclusive Longevity Investors Conference is right around the corner, taking place in Gstaad on September 28th-30th. 

Join the most exclusive gathering of world’s top longevity key opinion leaders, institutional and private investors, wealthy private investors, family offices and funds.